Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)

Completed

Conditions studied: Psoriasis

In brief

This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.

Key facts

Study ID

NCT05320159

Run by

Novartis Pharmaceuticals

People needed

17743

Starts

2021-02-03

Expected to finish

2021-03-31

Last updated by the study team

2022-07-01

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥1 orders/administrations for secukinumab within the index window (March 1, 2018 to August 31,2019 for the base analysis; March 1, 2018 to January 31, 2020 for the refresh analysis). The date of the first order or administration was be the index date
• Patients in the MMDS database with a diagnosis of PsO on or prior to the 1st secukinumab order/administration
• ≥18 years of age as of the index date
• To ensure capturing continuous patient activities in the EMR dataset, patients must have at least one more visit (any visit regardless of diagnosis) in addition to the index visit within the first 6 months after secukinumab initiation
• Patients must have at least one visit (any visit regardless of diagnosis) within the 12 months pre-index period

You may not qualify if…

• Evidence of secukinumab use in the 12-month pre-index period
• Data quality issues (missing age, gender, prescription order information)

Where it is running

• Novartis Investigative Site — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.